Abstract 15861: Adherence to the 2012 Canadian Lipid Screening Guidelines in Primary Prevention Patients: The CANHEART Study
Background: The 2012 Canadian Cardiovascular Society’s (CCS) lipid guidelines recommend universal lipid testing of males aged ≥40 and females ≥50 every 3 to 5 years and selective testing in high-risk patients aged <40 years. However, adherence to these recommendations is not known.
Methods: We conducted an analysis of lipid testing and results in 9.4 million primary prevention patients aged 20 to 105, as of January 2008, from Ontario, Canada in the Cardiovascular Health in Ambulatory Care Research Team (CANHEART) ‘big data’ cohort (www.canheart.ca) created through the linkage of multiple population-health databases. This cohort was followed for 5 years up to December 2012 to determine rates of lipid testing by sex and 10-year age bands. We also examined the frequency of elevated low-density lipoprotein (LDL) levels (>3.5 mmol/L or 135 mg/dL) in non-statin users and those without a history of hyperlipidemia. At LDLs above this level, consideration of statin therapy is recommended in those at intermediate cardiovascular risk in Canada.
Results: Overall, 69.2% of males and 74.1% of females aged 20 to 105 with no past history of cardiovascular disease had lipid testing over the 5-year time period. Rates of testing were highest (>80%) amongst males and females 50 to 79 years, but only 75% of males aged 40 to 49 received testing (Figure). Approximately half of Canadians aged <40 received testing, while rates of testing fell off in those aged ≥80 compared to those aged 50 to 79. Among adults tested, 33.1% of males and 27.4% of females had an LDL >3.5 mmol/L. The frequency of elevated LDL was greatest in males aged 40 to 49 and females aged 60 to 69, and was lowest in those aged 20 to 29 and aged 80 and over.
Conclusions: High rates of lipid testing in Canadians aged 50 to 79 are in concordance with Canadian lipid guidelines. The optimal lipid testing strategy in younger adults and the very elderly remains to be determined.
Author Disclosures: J.V. Tu: None. A. Chu: None. S. Johnston: None. C.A. Jackevicius: None. L.C. Maclagan: None. A.S. Bierman: None. W. Hogg: None. P.C. Austin: None. K. Tu: None. J.A. Udell: None. C.L. Atzema: None. P.P. Liu: None. M. Alabousi: None. J.J. Park: None. D.T. Ko: None.
- © 2016 by American Heart Association, Inc.